EUVIMEDEUVIMED entdecken
Open Access

TET2-driven activation of AGO2 links epigenetic remodeling to myeloid commitment and leukemia

Aleksey Lazarenkov iD, Gemma Valcárcel iD, Alba Martinez iD, Clara Berenguer iD, Anna V López-Rubio iD, Mireia Obiols iD, Claudia Fontanet, Ana Barba, Juan José Rodríguez-Sevilla iD, Gregoire Stik iD, Irmela Jeremias iD, Pablo Menendez iD und 1 weitere

Science Advances · 2026

DOI: 10.1126/sciadv.aee5701 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Aleksey Lazarenkov und 12 weiteren Autor:innen. Beteiligte Einrichtung: Epigenetic Control of Haematopoiesis Group, Josep Carreras Leukaemia Research Institute (IJC), Campus Can Ruti, Badalona, Spain. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins, DNA-Binding Proteins, Epigenesis, Genetic, Argonaute Proteins. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Worldwide Cancer Research, Instituto de Salud Carlos III, Spanish Ministry of Science and Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DNA methylation dynamics shape hematopoietic differentiation and leukemogenesis, yet how the dioxygenase TET2—frequently mutated in myeloid malignancies—directs lineage-specific regulatory programs remains unclear. Here, we integrated DNA methylation, chromatin accessibility, three-dimensional (3D) genome architecture, transcriptional profiling, and TET2 chromatin occupancy to define TET2-dependent control of human myeloid commitment. We found that TET2-bound regulatory regions gain short- and long-range chromatin interactions and that a distinct subset of distal, enhancer-enriched sites undergoes TET2-driven demethylation and activation. Among these, we identified and functionally validated an AGO2 myeloid-specific intragenic enhancer that is frequently hypermethylated in patients with TET2 -mutant acute myeloid leukemia. AGO2 expression stratifies patient survival, and AGO2 depletion abrogates leukemic engraftment in vivo. These findings uncover a TET2-AGO2 regulatory axis that integrates epigenetic remodeling, 3D genome reorganization, and leukemic fitness, and they highlight AGO2 as a potential biomarker and therapeutic target in myeloid leukemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene ProteinsDNA-Binding ProteinsEpigenesis, GeneticArgonaute ProteinsLeukemia, Myeloid, AcuteMyeloid CellsHumansDioxygenasesDNA MethylationAnimalsEnhancer Elements, GeneticMiceChromatinCell Differentiation

Substanzen

DioxygenasesTET2 protein, humanProto-Oncogene ProteinsDNA-Binding ProteinsArgonaute ProteinsAGO2 protein, humanChromatin

Autor:innen und Institutionen

  • Epigenetic Control of Haematopoiesis Group, Josep Carreras Leukaemia Research Institute (IJC), Campus Can Ruti, Badalona, Spain.
  • Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukaemia Research Institute (IJC), Campus Hospital Clínic, Barcelona, Spain.
  • Red de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III, Madrid, Spain.
  • Endocrine Regulatory Genomics, Department of Experimental & Health Sciences, University Pompeu Fabra, 08003 Barcelona, Spain.
  • Department of Hematology, Hospital Clinic Barcelona, Barcelona, Spain.
  • Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

ORCID-Profile: Aleksey Lazarenkov, Gemma Valcárcel, Alba Martinez, Clara Berenguer, Anna V López-Rubio, Mireia Obiols, Juan José Rodríguez-Sevilla, Gregoire Stik, Irmela Jeremias, Pablo Menendez, José Luis Sardina

Förderung

  • Worldwide Cancer Research
  • Instituto de Salud Carlos III
  • Spanish Ministry of Science and Universities
  • Departament de Recerca i Universitats de la Generalitat de Catalunya
  • MICIU/European Union NextGenerationEU
  • Deutsche José Carreras Leukämie-Siftung
  • Spanish Association against Cancer
  • FEDER/Spanish Ministry of Science and Innovation

Zitieren

APA

Lazarenkov, A., Valcárcel, G., Martinez, A., Berenguer, C., López-Rubio, A. V., Obiols, M., Fontanet, C., Barba, A., Rodríguez-Sevilla, J. J., Stik, G., Jeremias, I., Menendez, P., & Sardina, J. L. (2026). TET2-driven activation of AGO2 links epigenetic remodeling to myeloid commitment and leukemia. Science Advances. https://doi.org/10.1126/sciadv.aee5701

Vancouver

Lazarenkov A, Valcárcel G, Martinez A, Berenguer C, López-Rubio AV, Obiols M, et al. TET2-driven activation of AGO2 links epigenetic remodeling to myeloid commitment and leukemia. Science Advances. 2026. doi:10.1126/sciadv.aee5701

BibTeX
@article{Lazarenkov2026,
  author = {Lazarenkov, Aleksey and Valcárcel, Gemma and Martinez, Alba and Berenguer, Clara and López-Rubio, Anna V and Obiols, Mireia and Fontanet, Claudia and Barba, Ana and Rodríguez-Sevilla, Juan José and Stik, Gregoire and Jeremias, Irmela and Menendez, Pablo and Sardina, José Luis},
  title = {TET2-driven activation of AGO2 links epigenetic remodeling to myeloid commitment and leukemia},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aee5701}
}
Kostenlos starten →